Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-002505
Filing Date
2025-01-10
Accepted
2025-01-10 15:46:26
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 12503
2 EXHIBIT 99.3 tm252810d1_ex99-3.htm EX-99.3 18391
3 EXHIBIT 99.4 tm252810d1_ex99-4.htm EX-99.4 365318
  Complete submission text file 0001104659-25-002505.txt   397994
Mailing Address 333 LAKESIDE DR FOSTER CITY CA 94404
Business Address 333 LAKESIDE DR FOSTER CITY CA 94404 6505743000
GILEAD SCIENCES, INC. (Filed by) CIK: 0000882095 (see all company filings)

EIN.: 943047598 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address GEN DE WITTELAAN L11 A3 2800 MECHELEN C9 00000
Business Address GEN DE WITTELAAN L11 A3 2800 MECHELEN C9 00000 3215342900
GALAPAGOS NV (Subject) CIK: 0001421876 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88880 | Film No.: 25522708
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)